SOLIGENIX, INC. (SNGX)
Data as of , from SEC Form 4 filings.
See up to 3 months of SNGX. The 7-day demo opens the 1M and 3M ranges and puts SNGX on your watchlist.
Start 7-day demoLatest SNGX insider trades
Christopher J. Schaber - OfficerOpen-market purchase$20K- Jerome B. Zeldis - DirectorDerivative54 sh
- Jerome B. Zeldis - Director
About SOLIGENIX, INC. (SNGX)
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
- PRINCETON, NJ
- 14
- 1994
- XNAS
SNGX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 4 | 315,788 | |
| Derivative transaction | 47 | 7,767 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SNGX insider transactions (Form 4)
6020 Form 4 filings on record, the earliest from Dec 13, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jerome B. Zeldis - Director | Derivative | Stock Option (Right to Buy) | 54 | $0.00 | - | |
| Jerome B. Zeldis - Director | Derivative | Stock Option (Right to Buy) | 74 | $0.00 | - | |
| Jerome B. Zeldis - Director | Derivative | Stock Option (Right to Buy) | 128 | $0.00 | - | |
| Jerome B. Zeldis - Director | Derivative | Stock Option (Right to Buy) | 63 | $0.00 | - | |
| Jerome B. Zeldis - Director | Derivative | Stock Option (Right to Buy) | 121 | $0.00 | - | |
| Jerome B. Zeldis - Director | Derivative | Stock Option (Right to Buy) | 192 | $0.00 | - | |
| Robert J. Rubin - Director | Derivative | Stock Option (Right to Buy) | 54 | $0.00 | - | |
| Robert J. Rubin - Director | Derivative | Stock Option (Right to Buy) | 74 | $0.00 | - | |
| Robert J. Rubin - Director | Derivative | Stock Option (Right to Buy) | 128 | $0.00 | - | |
| Robert J. Rubin - Director | Derivative | Stock Option (Right to Buy) | 63 | $0.00 | - | |
| Robert J. Rubin - Director | Derivative | Stock Option (Right to Buy) | 121 | $0.00 | - | |
| Robert J. Rubin - Director | Derivative | Stock Option (Right to Buy) | 192 | $0.00 | - | |
| Diane L. Parks - Director | Derivative | Stock Option (Right to Buy) | 6 | $0.00 | - | |
| Diane L. Parks - Director | Derivative | Stock Option (Right to Buy) | 128 | $0.00 | - | |
| Diane L. Parks - Director | Derivative | Stock Option (Right to Buy) | 56 | $0.00 | - | |
| Diane L. Parks - Director | Derivative | Stock Option (Right to Buy) | 63 | $0.00 | - | |
| Diane L. Parks - Director | Derivative | Stock Option (Right to Buy) | 121 | $0.00 | - | |
| Diane L. Parks - Director | Derivative | Stock Option (Right to Buy) | 192 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Derivative | Stock Option (Right to Buy) | 54 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Derivative | Stock Option (Right to Buy) | 74 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Derivative | Stock Option (Right to Buy) | 128 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Derivative | Stock Option (Right to Buy) | 63 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Derivative | Stock Option (Right to Buy) | 121 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Derivative | Stock Option (Right to Buy) | 192 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 83 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 145 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 166 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 291 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 291 | $0.00 | - | |
| Oreola Donini - Officer | Derivative | Stock Option (Right to Buy) | 333 | $0.00 | - | |
| Jonathan L. Guarino - Officer | Derivative | Stock Option (Right to Buy) | 166 | $0.00 | - | |
| Jonathan L. Guarino - Officer | Derivative | Stock Option (Right to Buy) | 41 | $0.00 | - | |
| Jonathan L. Guarino - Officer | Derivative | Stock Option (Right to Buy) | 166 | $0.00 | - | |
| Jonathan L. Guarino - Officer | Derivative | Stock Option (Right to Buy) | 208 | $0.00 | - | |
| Jonathan L. Guarino - Officer | Derivative | Stock Option (Right to Buy) | 333 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 250 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 52 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 197 | $0.00 | - | |
| Christopher J. Schaber - Officer | Derivative | Stock Option (Right to Buy) | 583 | $0.00 | - | |
| Jerome B. Zeldis - Director | Grant or award | Stock Option (Right to Buy) | 78,947 | $0.00 | - | |
| Robert J. Rubin - Director | Grant or award | Stock Option (Right to Buy) | 78,947 | $0.00 | - | |
| Diane L. Parks - Director | Grant or award | Stock Option (Right to Buy) | 78,947 | $0.00 | - | |
| Anthony Gregg Lapointe - Director | Grant or award | Stock Option (Right to Buy) | 78,947 | $0.00 | - | |
| Christopher J. Schaber - Officer | Open-market purchase | Common Stock | 15,132 | $1.32 footnote F1 | $20K | |
| ||||||
| Jonathan L. Guarino - Officer | Grant or award | Option (Right to Buy) | 20,000 | $0.00 | - | |
| Diane L. Parks | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Oreola Donini - Officer | Grant or award | Option (Right to Buy) | 20,000 | $0.00 | - | |
| Richard Straube - Officer | Grant or award | Option (Right to Buy) | 12,000 | $0.00 | - | |
| Jerome B. Zeldis | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Robert J. Rubin | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Anthony Gregg Lapointe | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Christopher J. Schaber - Officer | Grant or award | Option (Right to Buy) | 45,000 | $0.00 | - | |
SNGX insider trading FAQ
What is the latest insider trade for SNGX?
SOLIGENIX, INC. (SNGX) had 11 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for SNGX runs to 20 Form 4 filings, the earliest from 2024-12-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SNGX stock?
No insider purchases of SNGX were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling SNGX stock?
No insider sales of SNGX were filed in the last 90 days.
Where can I see SNGX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SNGX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jerome B. Zeldis view on EDGAR
- - Robert J. Rubin view on EDGAR
- - Diane L. Parks view on EDGAR
- - Anthony Gregg Lapointe view on EDGAR
- - Oreola Donini view on EDGAR
- - Jonathan L. Guarino view on EDGAR
- - Christopher J. Schaber view on EDGAR
- - Jerome B. Zeldis view on EDGAR
- - Robert J. Rubin view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where SNGX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SNGX with a 7-day demo
- SNGX on your watchlist
- Every SNGX Form 4 filing on record
- Up to 3 months of SNGX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
